1
|
Giacoletti G, Price T, Hoelz LVB, Shremo Msdi A, Cossin S, Vazquez-Falto K, Amorim Fernandes TV, Santos de Pontes V, Wang H, Boechat N, Nornoo A, Brust TF. A Selective Adenylyl Cyclase 1 Inhibitor Relieves Pain Without Causing Tolerance. Front Pharmacol 2022; 13:935588. [PMID: 35899113 PMCID: PMC9310748 DOI: 10.3389/fphar.2022.935588] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Accepted: 06/20/2022] [Indexed: 11/13/2022] Open
Abstract
Among the ten different adenylyl cyclase isoforms, studies with knockout animals indicate that inhibition of AC1 can relieve pain and reduce behaviors linked to opioid dependence. We previously identified ST034307 as a selective inhibitor of AC1. The development of an AC1-selective inhibitor now provides the opportunity to further study the therapeutic potential of inhibiting this protein in pre-clinical animal models of pain and related adverse reactions. In the present study we have shown that ST034307 relives pain in mouse models of formalin-induced inflammatory pain, acid-induced visceral pain, and acid-depressed nesting. In addition, ST034307 did not cause analgesic tolerance after chronic dosing. We were unable to detect ST034307 in mouse brain following subcutaneous injections but showed a significant reduction in cAMP concentration in dorsal root ganglia of the animals. Considering the unprecedented selectivity of ST034307, we also report the predicted molecular interaction between ST034307 and AC1. Our results indicate that AC1 inhibitors represent a promising new class of analgesic agents that treat pain and do not result in tolerance or cause disruption of normal behavior in mice. In addition, we outline a unique binding site for ST034307 at the interface of the enzyme’s catalytic domain.
Collapse
Affiliation(s)
- Gianna Giacoletti
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
| | - Tatum Price
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
| | - Lucas V. B. Hoelz
- Laboratório de Síntese de Fármacos—LASFAR, Instituto de Tecnologia em Fármacos, Farmanguinhos—FIOCRUZ, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Abdulwhab Shremo Msdi
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
| | - Samantha Cossin
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
| | - Katerina Vazquez-Falto
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
| | - Tácio V. Amorim Fernandes
- Laboratório de Síntese de Fármacos—LASFAR, Instituto de Tecnologia em Fármacos, Farmanguinhos—FIOCRUZ, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- Instituto Nacional de Metrologia, Qualidade e Tecnologia—INMETRO, Rio de Janeiro, Brazil
| | - Vinícius Santos de Pontes
- Laboratório de Síntese de Fármacos—LASFAR, Instituto de Tecnologia em Fármacos, Farmanguinhos—FIOCRUZ, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Hongbing Wang
- Department of Physiology, Michigan State University, East Lansing, MI, United States
| | - Nubia Boechat
- Laboratório de Síntese de Fármacos—LASFAR, Instituto de Tecnologia em Fármacos, Farmanguinhos—FIOCRUZ, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Adwoa Nornoo
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
| | - Tarsis F. Brust
- Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United States
- *Correspondence: Tarsis F. Brust,
| |
Collapse
|
2
|
Silveira FF, de Souza JO, Hoelz LVB, Campos VR, Jabor VAP, Aguiar ACC, Nonato MC, Albuquerque MG, Guido RVC, Boechat N, Pinheiro LCS. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors. Eur J Med Chem 2020; 209:112941. [PMID: 33158577 DOI: 10.1016/j.ejmech.2020.112941] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 10/09/2020] [Accepted: 10/11/2020] [Indexed: 12/13/2022]
Abstract
In this work, we designed and synthesized 35 new triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives as P. falciparum inhibitors (3D7 strain). Thirty compounds exhibited anti-P. falciparum activity, with IC50 values ranging from 0.030 to 9.1 μM. The [1,2,4]triazolo[1,5-a]pyrimidine derivatives were more potent than the pyrazolo[1,5-a]pyrimidine and quinoline analogues. Compounds 20, 21, 23 and 24 were the most potent inhibitors, with IC50 values in the range of 0.030-0.086 μM and were equipotent to chloroquine. In addition, the compounds were selective, showing no cytotoxic activity against the human hepatoma cell line HepG2. All [1,2,4]triazolo[1,5-a]pyrimidine derivatives inhibited PfDHODH activity in the low micromolar to low nanomolar range (IC50 values of 0.08-1.3 μM) and did not show significant inhibition against the HsDHODH homologue (0-30% at 50 μM). Molecular docking studies indicated the binding mode of [1,2,4]triazolo[1,5-a]pyrimidine derivatives to PfDHODH, and the highest interaction affinities for the PfDHODH enzyme were in agreement with the in vitro experimental evaluation. Thus, the most active compounds against P. falciparum parasites 20 (R = CF3, R1 = F; IC50 = 0.086 μM), 21 (R = CF3; R1 = CH3; IC50 = 0.032 μM), 23, (R = CF3, R1 = CF3; IC50 = 0.030 μM) and 24 (R = CF3, 2-naphthyl; IC50 = 0.050 μM) and the most active inhibitor against PfDHODH 19 (R = CF3, R1 = Cl; IC50 = 0.08 μM - PfDHODH) stood out as new lead compounds for antimalarial drug discovery. Their potent in vitro activity against P. falciparum and the selective inhibition of the PfDHODH enzyme strongly suggest that this is the mechanism of action underlying this series of new [1,2,4]triazolo[1,5-a]pyrimidine derivatives.
Collapse
Affiliation(s)
- Flávia F Silveira
- Laboratorio de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundacao Oswaldo Cruz. Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, 21041-250, Brazil; Programa de Pós-Graduação em Química, PGQu Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Juliana O de Souza
- Instituto de Física de São Carlos, Universidade de São Paulo, Av. João Dagnone, 1.100, Jd. Santa Angelina, São Carlos, SP, Brazil
| | - Lucas V B Hoelz
- Laboratorio de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundacao Oswaldo Cruz. Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, 21041-250, Brazil
| | - Vinícius R Campos
- Departamento de Química Orgânica, Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, Niterói, RJ, Brazil
| | - Valquíria A P Jabor
- Laboratório de Cristalografia de Proteínas, Departamento de Ciências BioMoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Avenida do Café s/n Monte Alegre, 14040-903, Ribeirão Preto, SP, Brazil
| | - Anna C C Aguiar
- Instituto de Física de São Carlos, Universidade de São Paulo, Av. João Dagnone, 1.100, Jd. Santa Angelina, São Carlos, SP, Brazil
| | - M Cristina Nonato
- Laboratório de Cristalografia de Proteínas, Departamento de Ciências BioMoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Avenida do Café s/n Monte Alegre, 14040-903, Ribeirão Preto, SP, Brazil
| | - Magaly G Albuquerque
- Programa de Pós-Graduação em Química, PGQu Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Rafael V C Guido
- Instituto de Física de São Carlos, Universidade de São Paulo, Av. João Dagnone, 1.100, Jd. Santa Angelina, São Carlos, SP, Brazil.
| | - Nubia Boechat
- Laboratorio de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundacao Oswaldo Cruz. Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, 21041-250, Brazil; Programa de Pós-Graduação em Química, PGQu Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
| | - Luiz C S Pinheiro
- Laboratorio de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundacao Oswaldo Cruz. Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ, 21041-250, Brazil.
| |
Collapse
|
3
|
Pinheiro LCS, Hoelz LVB, Ferreira MLG, Oliveira LG, Pereira RFA, do Valle AM, André LSP, Scaffo J, Pinheiro FR, Ribeiro TAN, Sachs D, Pascoal ACRF, Boechat N, Aguiar-Alves F. Synthesis of benzoylthiourea derivatives and analysis of their antibacterial performance against planktonic Staphylococcus aureus and its biofilms. Lett Appl Microbiol 2020; 71:645-651. [PMID: 32725897 DOI: 10.1111/lam.13359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 07/19/2020] [Accepted: 07/19/2020] [Indexed: 11/30/2022]
Abstract
Following the appearance of several antimicrobial agents to control the spread of infections, two major challenges have emerged: (i) the occurrence and blowout of multiresistant bacteria and the increase of chronic diseases and (ii) difficult-to-eradicate infections. In this study, we tested five benzoylthiourea derivatives for their ability to inhibit and stop bacterial growth and evaluated the possible influence of 1,2,4-triazolyl-benzoylthiourea derivative 4 on the formation and eradication of Staphylococcus aureus biofilms. Benzoylthiourea derivatives 4, 6, 10, 11 and 13 were obtained in one or two steps with low cost and subjected to tests to identify their minimum inhibitory concentration (MIC) and minimum bactericidal concentration. In vitro tests were also performed to assess their effects on biofilm formation and in preformed biofilms and scanning electron microscopy was used to visualize the effects on biofilm formation. The 1,2,4-triazolyl-benzoylthiourea derivative 4 showed bacteriostatic activity against the S. aureus HU25 clinical strain with an MIC of 16 µg ml-1 , which is below the toxic concentration (at 2500 µg ml-1 , 62·25% of the cells remained viable). Compound 4 also effectively prevented biofilm formation at the three subinhibitory concentrations tested (1/2 MIC, 1/4 MIC and 1/8 MIC) as confirmed by scanning electron microscopy. For breakdown of formed biofilms, the main influence was at a subinhibitory concentration (1/2 MIC). These findings make compound 4 a strong candidate for studies on the development of new antimicrobial and antibiofilm agents.
Collapse
Affiliation(s)
- L C S Pinheiro
- Drug Synthesis Department, Drug Technology Institute, Farmanguinhos - FIOCRUZ, Oswaldo Cruz Foundation, Manguinhos, RJ, Brazil
| | - L V B Hoelz
- Drug Synthesis Department, Drug Technology Institute, Farmanguinhos - FIOCRUZ, Oswaldo Cruz Foundation, Manguinhos, RJ, Brazil
| | - M L G Ferreira
- Drug Synthesis Department, Drug Technology Institute, Farmanguinhos - FIOCRUZ, Oswaldo Cruz Foundation, Manguinhos, RJ, Brazil
| | - L G Oliveira
- Drug Synthesis Department, Drug Technology Institute, Farmanguinhos - FIOCRUZ, Oswaldo Cruz Foundation, Manguinhos, RJ, Brazil
| | - R F A Pereira
- Laboratory of Molecular Epidemiology and Biotechnology/Rodolpho Albino University Laboratory, Fluminense Federal University, Niteroi, RJ, Brazil.,Postgraduate Program in Science and Biotechnology, Fluminense Federal University, Niteroi, RJ, Brazil
| | - A M do Valle
- Laboratory of Molecular Epidemiology and Biotechnology/Rodolpho Albino University Laboratory, Fluminense Federal University, Niteroi, RJ, Brazil
| | - L S P André
- Laboratory of Molecular Epidemiology and Biotechnology/Rodolpho Albino University Laboratory, Fluminense Federal University, Niteroi, RJ, Brazil.,Postgraduate Program in Pathology, Fluminense Federal University, Niteroi, RJ, Brazil
| | - J Scaffo
- Laboratory of Molecular Epidemiology and Biotechnology/Rodolpho Albino University Laboratory, Fluminense Federal University, Niteroi, RJ, Brazil
| | - F R Pinheiro
- Laboratory of Molecular Epidemiology and Biotechnology/Rodolpho Albino University Laboratory, Fluminense Federal University, Niteroi, RJ, Brazil.,Postgraduate Program in Applied Microbiology and Parasitology, Fluminense Federal University, Niterói, RJ, Brazil
| | - T A N Ribeiro
- Institute of Physics and Chemistry, Federal University of Itajubá, Itajubá, MG, Brazil
| | - D Sachs
- Institute of Physics and Chemistry, Federal University of Itajubá, Itajubá, MG, Brazil
| | - A C R F Pascoal
- Department of Basic Sciences, Nova Friburgo Health Institute, Fluminense Federal University, Nova Friburgo, RJ, Brazil
| | - N Boechat
- Drug Synthesis Department, Drug Technology Institute, Farmanguinhos - FIOCRUZ, Oswaldo Cruz Foundation, Manguinhos, RJ, Brazil
| | - F Aguiar-Alves
- Laboratory of Molecular Epidemiology and Biotechnology/Rodolpho Albino University Laboratory, Fluminense Federal University, Niteroi, RJ, Brazil.,Postgraduate Program in Pathology, Fluminense Federal University, Niteroi, RJ, Brazil.,Postgraduate Program in Applied Microbiology and Parasitology, Fluminense Federal University, Niterói, RJ, Brazil
| |
Collapse
|
4
|
Feitosa LM, da Silva ER, Hoelz LVB, Souza DL, Come JAASS, Cardoso-Santos C, Batista MM, Soeiro MDNC, Boechat N, Pinheiro LCS. New pyrazolopyrimidine derivatives as Leishmania amazonensis arginase inhibitors. Bioorg Med Chem 2019; 27:3061-3069. [PMID: 31176565 DOI: 10.1016/j.bmc.2019.05.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 05/10/2019] [Accepted: 05/16/2019] [Indexed: 11/26/2022]
Abstract
Arginase performs the first enzymatic step in polyamine biosynthesis in Leishmania and represents a promising target for drug development. Polyamines in Leishmania are involved in trypanothione synthesis, which neutralize the oxidative burst of reactive oxygen species (ROS) and nitric oxide (NO) that are produced by host macrophages to kill the parasite. In an attempt to synthesize arginase inhibitors, six 1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives with different substituents at the 4-position of the phenyl group were synthesized. All compounds were initially tested at 100 µM concentration against Leishmania amazonensis ARG (LaARG), showing inhibitory activity ranging from 36 to 74%. Two compounds, 1 (R=H) and 6 (R=CF3), showed arginase inhibition >70% and IC50 values of 12 µM and 47 µM, respectively. Thus, the kinetics of LaARG inhibition were analyzed for compounds 1 and 6 and revealed that these compounds inhibit the enzyme by an uncompetitive mechanism, showing Kis values, and dissociation constants for ternary complex enzyme-substrate-inhibitor, of 8.5 ± 0.9 µM and 29 ± 5 µM, respectively. Additionally, the molecular docking studies proposed that these two uncompetitive inhibitors interact with different LaARG binding sites, where compound 1 forms more H-bond interactions with the enzyme than compound 6. These compounds showed low activity against L. amazonensis free amastigotes obtained from mice lesions when assayed with as much as 30 µM. The maximum growth inhibition reached was between 20 and 30% after 48 h of incubation. These results suggest that this system can be promising for the design of potential antileishmanial compounds.
Collapse
Affiliation(s)
- Livia M Feitosa
- Departamento de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ 21041-250, Brazil; Programa de Pos-graduacao em Quimica, PGQu Instituto de Quimica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Edson R da Silva
- Departamento de Medicina Veterinaria, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de Sao Paulo, Pirassununga, SP, Brazil.
| | - Lucas V B Hoelz
- Departamento de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ 21041-250, Brazil
| | - Danielle L Souza
- Departamento de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ 21041-250, Brazil
| | - Julio A A S S Come
- Programa de Pos-graduacao em Biociencia Animal, Faculdade de Zootecnia e Engenahria de alimentos, Universidade de São Paulo, Pirassununga, SP, Brazil
| | - Camila Cardoso-Santos
- Laboratorio de Biologia Celular, Instituto Oswaldo Cruz, IOC - FIOCRUZ, Fundacao Oswaldo Cruz, Avenida Brasil 4365, Rio de Janeiro, RJ, Brazil
| | - Marcos M Batista
- Laboratorio de Biologia Celular, Instituto Oswaldo Cruz, IOC - FIOCRUZ, Fundacao Oswaldo Cruz, Avenida Brasil 4365, Rio de Janeiro, RJ, Brazil
| | - Maria de Nazare C Soeiro
- Laboratorio de Biologia Celular, Instituto Oswaldo Cruz, IOC - FIOCRUZ, Fundacao Oswaldo Cruz, Avenida Brasil 4365, Rio de Janeiro, RJ, Brazil
| | - Nubia Boechat
- Departamento de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ 21041-250, Brazil.
| | - Luiz C S Pinheiro
- Departamento de Sintese de Farmacos, Instituto de Tecnologia em Farmacos, Farmanguinhos - FIOCRUZ, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro, RJ 21041-250, Brazil
| |
Collapse
|
5
|
Gonzaga DTG, Oliveira FH, von Ranke NL, Pinho GQ, Salles JP, Bello ML, Rodrigues CR, Castro HC, de Souza HVCM, Reis CRC, Leme RPP, Mafra JCM, Pinheiro LCS, Hoelz LVB, Boechat N, Faria RX. Synthesis, Biological Evaluation, and Molecular Modeling Studies of New Thiadiazole Derivatives as Potent P2X7 Receptor Inhibitors. Front Chem 2019; 7:261. [PMID: 31134177 PMCID: PMC6511888 DOI: 10.3389/fchem.2019.00261] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 04/01/2019] [Indexed: 01/01/2023] Open
Abstract
Twenty new 2-(1H-pyrazol-1-yl)-1,3,4-thiadiazole analogs were synthetized to develop P2X7 receptor (P2X7R) inhibitors. P2X7R inhibition in vitro was evaluated in mouse peritoneal macrophages, HEK-293 cells transfected with hP2X7R (dye uptake assay), and THP-1 cells (IL-1β release assay). The 1-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrazol-5-amine derivatives 9b, 9c, and 9f, and 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-(4-fluorophenyl)-1,3,4-thiadiazole (11c) showed inhibitory effects with IC50 values ranging from 16 to 122 nM for reduced P2X7R-mediated dye uptake and 20 to 300 nM for IL-1β release. In addition, the in vitro ADMET profile of the four most potent derivatives was determined to be in acceptable ranges concerning metabolic stability and cytotoxicity. Molecular docking and molecular dynamics simulation studies of the molecular complexes human P2X7R/9f and murine P2X7R/9f indicated the putative intermolecular interactions. Compound 9f showed affinity mainly for the Arg268, Lys377, and Asn266 residues. These results suggest that 2-(1H-pyrazol-1-yl)-1,3,4-thiadiazole analogs may be promising novel P2X7R inhibitors with therapeutic potential.
Collapse
Affiliation(s)
- Daniel T G Gonzaga
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil.,Instituto Biomédico, Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, Brazil
| | - Felipe H Oliveira
- Laboratório de Toxoplasmose e Outras Protozooses, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
| | - N L von Ranke
- Departamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - G Q Pinho
- Laboratório de Toxoplasmose e Outras Protozooses, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Juliana P Salles
- Laboratório de Toxoplasmose e Outras Protozooses, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Murilo L Bello
- Departamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Carlos R Rodrigues
- Departamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Helena C Castro
- Laboratório de Antibióticos, Bioquímica, Ensino e Modelagem Molecular-LABiEMol, Universidade Federal Fluminense, Niterói, Brazil
| | - Hellen V C M de Souza
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil
| | - Caroline R C Reis
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil
| | - Rennan P P Leme
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil
| | - João C M Mafra
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil
| | - Luiz C S Pinheiro
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil
| | - Lucas V B Hoelz
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil
| | - Nubia Boechat
- Departamento de Síntese de Fármacos Manguinhos, Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil
| | - Robson X Faria
- Instituto Biomédico, Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, Brazil
| |
Collapse
|
6
|
Azevedo LD, Bastos MM, Vasconcelos FC, Hoelz LVB, Junior FPS, Dantas RF, de Almeida ACM, de Oliveira AP, Gomes LC, Maia RC, Boechat N. Imatinib derivatives as inhibitors of K562 cells in chronic myeloid leukemia. Med Chem Res 2017. [DOI: 10.1007/s00044-017-1993-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
7
|
Hoelz LVB, Leal VF, Rodrigues CR, Pascutti PG, Albuquerque MG, Muri EMF, Dias LRS. Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent: insights on the inhibition mechanism in acidic pH. J Biomol Struct Dyn 2015; 34:1969-78. [PMID: 26414241 DOI: 10.1080/07391102.2015.1100139] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The major cysteine protease of Trypanosoma cruzi, cruzain (CRZ), has been described as a therapeutic target for Chagas' disease, which affects millions of people worldwide. Thus, a series of CRZ inhibitors has been studied, including a new competitive inhibitor, Nequimed176 (NEQ176). Nevertheless, the structural and dynamic basis for CRZ inhibition remains unclear. Hoping to contribute to this ever-growing understanding of timescale dynamics in the CRZ inhibition mechanism, we have performed the first study using 100 ns of molecular dynamics (MD) simulations of two CRZ systems in an aqueous solvent under pH 5.5: CRZ in the apo form (ligand free) and CRZ complexed to NEQ176. According to the MD simulations, the enzyme adopts an open conformation in the apo form and a closed conformation in the NEQ176-CRZ complex. We also suggest that this closed conformation is related to the hydrogen-bonding interactions between NEQ176 and CRZ, which occurs through key residues, mainly Gly66, Met68, Asn69, and Leu160. In addition, the cross-correlation analysis shows evidence of the correlated motions among Ala110-Asp140, Leu160-Gly189, and Glu190-Gly215 subdomains, as well as, the movements related to Ala1-Thr59 and Asp60-Pro90 regions seem to be crucial for CRZ activity.
Collapse
Affiliation(s)
- L V B Hoelz
- a Laboratório de Química Medicinal, Faculdade de Farmácia , Universidade Federal Fluminense (UFF) , Rua Mário Viana 523, Santa Rosa , Niterói , RJ 24241-000 , Brazil
| | - V F Leal
- a Laboratório de Química Medicinal, Faculdade de Farmácia , Universidade Federal Fluminense (UFF) , Rua Mário Viana 523, Santa Rosa , Niterói , RJ 24241-000 , Brazil
| | - C R Rodrigues
- b Laboratório ModMolQSAR, Faculdade de Farmácia , Universidade Federal do Rio de Janeiro (UFRJ) , Av. Carlos Chagas Filho 373, CCS, Rio de Janeiro , RJ 21941-599 , Brazil
| | - P G Pascutti
- c Laboratório de Modelagem e Dinâmica Molecular , Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro (UFRJ) , Av. Carlos Chagas Filho 373, CCS, Rio de Janeiro , RJ 21941-902 , Brazil
| | - M G Albuquerque
- d Laboratório de Modelagem Molecular , Instituto de Química, Universidade Federal do Rio de Janeiro (UFRJ) , Av. Athos da Silveira Ramos 149, CT, Rio de Janeiro , RJ 21949-900 , Brazil
| | - E M F Muri
- a Laboratório de Química Medicinal, Faculdade de Farmácia , Universidade Federal Fluminense (UFF) , Rua Mário Viana 523, Santa Rosa , Niterói , RJ 24241-000 , Brazil
| | - L R S Dias
- a Laboratório de Química Medicinal, Faculdade de Farmácia , Universidade Federal Fluminense (UFF) , Rua Mário Viana 523, Santa Rosa , Niterói , RJ 24241-000 , Brazil
| |
Collapse
|
8
|
Gazos-Lopes F, Oliveira MM, Hoelz LVB, Vieira DP, Marques AF, Nakayasu ES, Gomes MT, Salloum NG, Pascutti PG, Souto-Padrón T, Monteiro RQ, Lopes AH, Almeida IC. Structural and functional analysis of a platelet-activating lysophosphatidylcholine of Trypanosoma cruzi. PLoS Negl Trop Dis 2014; 8:e3077. [PMID: 25101628 PMCID: PMC4125143 DOI: 10.1371/journal.pntd.0003077] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Accepted: 06/13/2014] [Indexed: 12/15/2022] Open
Abstract
Background Trypanosoma cruzi is the causative agent of the life-threatening Chagas disease, in which increased platelet aggregation related to myocarditis is observed. Platelet-activating factor (PAF) is a potent intercellular lipid mediator and second messenger that exerts its activity through a PAF-specific receptor (PAFR). Previous data from our group suggested that T. cruzi synthesizes a phospholipid with PAF-like activity. The structure of T. cruzi PAF-like molecule, however, remains elusive. Methodology/Principal findings Here, we have purified and structurally characterized the putative T. cruzi PAF-like molecule by electrospray ionization-tandem mass spectrometry (ESI-MS/MS). Our ESI-MS/MS data demonstrated that the T. cruzi PAF-like molecule is actually a lysophosphatidylcholine (LPC), namely sn-1 C18:1(delta 9)-LPC. Similar to PAF, the platelet-aggregating activity of C18:1-LPC was abrogated by the PAFR antagonist, WEB 2086. Other major LPC species, i.e., C16:0-, C18:0-, and C18:2-LPC, were also characterized in all T. cruzi stages. These LPC species, however, failed to induce platelet aggregation. Quantification of T. cruzi LPC species by ESI-MS revealed that intracellular amastigote and trypomastigote forms have much higher levels of C18:1-LPC than epimastigote and metacyclic trypomastigote forms. C18:1-LPC was also found to be secreted by the parasite in extracellular vesicles (EV) and an EV-free fraction. A three-dimensional model of PAFR was constructed and a molecular docking study was performed to predict the interactions between the PAFR model and PAF, and each LPC species. Molecular docking data suggested that, contrary to other LPC species analyzed, C18:1-LPC is predicted to interact with the PAFR model in a fashion similar to PAF. Conclusions/Significance Taken together, our data indicate that T. cruzi synthesizes a bioactive C18:1-LPC, which aggregates platelets via PAFR. We propose that C18:1-LPC might be an important lipid mediator in the progression of Chagas disease and its biosynthesis could eventually be exploited as a potential target for new therapeutic interventions. Chagas disease, caused by the parasite Trypanosoma cruzi, was exclusively confined to Latin America but it has recently spread to other regions of the world. Chagas disease affects 8–10 million people and kills thousands of them every year. Lysophosphatidylcholine (LPC) is a major bioactive phospholipid of human plasma low-density lipoproteins (LDL). Platelet-activating factor (PAF) is a phospholipid similar to LPC and a potent intercellular mediator. Both PAF and LPC have been reported to act on mammalian cells through PAF receptor (PAFR). Previous data from our group suggested that T. cruzi produces a phospholipid with PAF activity. Here, we describe the structural and functional analysis of different species of LPC from T. cruzi, including a LPC with a fatty acid chain of 18 carbon atoms and one double bond (C18:1-LPC). We also show that C18:1-LPC is able to induce rabbit platelet aggregation, which is abrogated by a PAFR antagonist. In addition, a three-dimensional model of human PAFR was constructed. Contrary to other T. cruzi LPC molecules, C18:1-LPC is predicted to interact with the PAFR model in a fashion similar to PAF. Further studies are needed to validate the biosynthesis of T. cruzi C18:1-LPC as a potential drug target in Chagas disease.
Collapse
Affiliation(s)
- Felipe Gazos-Lopes
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
| | - Mauricio M. Oliveira
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Lucas V. B. Hoelz
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco G, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Danielle P. Vieira
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Alexandre F. Marques
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
- Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Parasitologia, Pampulha, Belo Horizonte, Minas Gerais, Brazil
| | - Ernesto S. Nakayasu
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
| | - Marta T. Gomes
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
- Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco H, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Nasim G. Salloum
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
| | - Pedro G. Pascutti
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco G, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Thaïs Souto-Padrón
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Robson Q. Monteiro
- Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco H, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Angela H. Lopes
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
- * E-mail: (AHL); (ICA)
| | - Igor C. Almeida
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
- * E-mail: (AHL); (ICA)
| |
Collapse
|
9
|
Santos-Filho OA, Forge D, Hoelz LVB, de Freitas GBL, Marinho TO, Araújo JQ, Albuquerque MG, de Alencastro RB, Boechat N. CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of Pneumocystis carinii dihydrofolate reductase. J Mol Model 2012; 18:4061-72. [DOI: 10.1007/s00894-012-1399-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2012] [Accepted: 03/06/2012] [Indexed: 11/28/2022]
|
10
|
Abstract
This paper provides a description of tribromoisocyanuric acid (TBCA), a new reagent used as a source of electrophilic bromine (Br+) in organic synthesis, including in Green Chemistry procedures. Its applications embrace the bromination of alkenes, β-dicarbonyl compounds and deactivated arenes, as well as oxidations of urazoles, bisurazoles, and thiols.
Collapse
|